Cancer Res. 2005 Feb 15;11(4):1447-53.
evaluation of expressions of cyclin E and p53 proteins as prognostic
factors for patients with gastric cancer.
Bani-Hani KE, Almasri NM, Khader YS, Sheyab FM, Karam HN.
Department of Surgery, King Abdullah University Hospital, Faculty of
University of Science and Technology, P.O. Box 3030 Irbid, 22110,
BACKGROUND: There is a lack of consistency regarding the
prognostic value of cyclin E overexpression in gastric cancer
(gastric cancer). Our aim was to report on this overexpression
and to analyze its correlations with the clinicopathologic
variables. Another aim was to examine if aberrant expression of
both cyclin E and p53 might increase the malignant potential of
METHODS: Specimens from 89 patients with gastric cancer treated
with "curative" intent were evaluated for cyclin E and p53
expressions using immunohistochemical method. The correlations
between cyclin E overexpression alone or in combination with p53
expression and the patient's clinicopathologic variables were
RESULTS: Cyclin E overexpression and p53 expression were shown
in 35 (39.3%) and 46 (51.7%) tumors, respectively. The incidence
of cyclin E overexpression was significantly higher in deeply
invasive cancers (P < 0.0001), in cancers with lymph node
metastasis (P = 0.003), and in cancers with advanced stages (P <
0.0001). There were no significant correlations with other
clinicopathologic variables. Patients in whom their tumors
showed cyclin E overexpression alone or in combination with p53
survived less than patients with negative cyclin E tumors.
Multivariate analysis revealed that combined cyclin E
overexpression and p53 expression was significantly associated
with poor survival after adjusting for other variables (hazard
ratio, 3.12; P = 0.009).
CONCLUSIONS: Cyclin E overexpression is a common event in
gastric cancer. Gastric cancer with cyclin E overexpression
exhibit increased aggressiveness in the presence of aberrant
p53. The combination of cyclin E overexpression with the p53
expression in gastric cancer further distinguished a subgroup of
patients with poor prognosis.
PMID: 15746045 [PubMed - in process]